Aurinia Pharmaceuticals Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-04-18: Measure Net Revenue.
- 2023-04-18: Measure Net Revenue.
- 2024-05-03: Measure Net Revenue.
- 2024-05-03: Measure Net Revenue.
| Proxy filed | Measure |
|---|---|
| 2023-04-18 | Net Revenue |
| 2023-04-18 | Net Revenue |
| 2024-05-03 | Net Revenue |
| 2024-05-03 | Net Revenue |
| 2025-04-17 | Net revenue |
| 2025-04-17 | Net revenue |
| 2026-04-21 | Net revenue |
| 2026-04-21 | Net revenue |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |